Treat cancer and reverse fibrosis

We are a biotech company with a mission to treat cancer and reverse fibrosis. To this end, we are rapidly advancing our clinical pipeline of anti-Claudin-1 monoclonal antibodies.

Our team is committed to unlocking the broad potential of our therapeutic target Claudin-1 and bringing new treatments to those in need.

Transformative Claudin-1 antibodies

We are the world leader in developing anti-Claudin-1 treatment. Our first-in-class antibodies specifically target exposed Claudin-1 to open the stiff extracellular matrix, block disease signaling, and in cancer, selectively kill tumor cells.

R&D pipeline

We have developed a promising pipeline of anti-Claudin-1 antibodies. Our two clinical candidates are in Phase 1/2 for solid tumors and Phase 2 for organ fibrosis, respectively. Beyond conventional therapies, our preclinical programs feature anti-Claudin-1 antibody-drug conjugates, bispecific antibodies, and T-cell engagers.

Inspired leadership

Our carefully chosen team values collaboration, hard work and shares the belief that anti-Claudin-1 therapies will make a difference for patients. Our highly experienced leadership team is supported by a Board of Directors and a Scientific Advisory Board made up of industry veterans, entrepreneurs and esteemed scientists.

Alentis news

December 06, 2023

ALENTIS EXPANDS LEADERSHIP TEAM WITH THE APPOINTMENT OF RIZWAN VELJI AS CHIEF BUSINESS OFFICER

December 05, 2023

ALENTIS DOSES FIRST ANCA-ASSOCIATED VASCULITIS  PATIENT IN PHASE 2 CLINICAL TRIAL OF LIXUDEBART (ALE.F02)

November 16, 2023

ALENTIS DOSES FIRST PATIENT IN PHASE 1/2 CLINICAL TRIAL OF ALE.C04 IN HNSCC